UNIVERSAL IBOGAINE Aktie

 

FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN UNIVERSAL IBOGAINE INC. JC4 CA91360F1099 AB/FROM ONWARDS 10.04.2025 15:57 CET...

  Calgary, AB – TheNewswire - April 3, 2025 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, advises that it has agreed to settle a portion, totalling $106,200, of arrears consulting fees owed to its CEO, Nicholas Karos (the “Debt”).  UI is in process of applying to the TSX Venture Exchange (the “TSXV”) to allow the issuance of up to 4,248,000 common shares, at a minimum price of $0.025 per share (or such other minimum price and number of common shares as required by the TSXV) in settlement of the Debt. UI also notes that it had previously advised (see News Release of February 5, 2025) that the Alberta Securities Commission (the “ASC”, its principal regulator) had ordered that all trading and purchasing of securities of the Company cease (the “Cease Trade Order”) due to the Company's failure to file by the required deadline its audited financial statements and related...

  Calgary, AB – February 5, 2025 – TheNewswire - Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, provides the following update related to the previously issued Management Cease Trade Order (“MCTO”). As was noted in the Company's prior news releases (last dated January 27, 2025), UI was not in a position to complete the filing of its annual audited consolidated financial statements for the year ended July 31, 2024 (the “Financial Statements”), its related management's discussion and analysis (“MD&A”), and the Chief Executive Officer and Chief Financial Officer certifications (collectively, the "Required Filings") past the prescribed deadline of November 28, 2024.  The Company was granted a MCTO by the Alberta Securities Commission (the “ASC”), its principal regulator, on November 29, 2024 and thereafter was required to file bi-weekly default status report...

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL UNIVERSAL IBOGAINE INC. JC4 CA91360F1099 BAW/UFN...

Instrument ID [10326961] (JC4 - CA91360F1099) suspended...

  Calgary, AB – TheNewswire - January 27, 2025 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, provides the following bi-weekly default status report update: Management Cease Trade Order (“MCTO”) Further to the Company's prior news releases (dated November 18, November 26, December 11, and December 27, 2024 and January 13, 2025), the Company is providing this bi-weekly default status report (the “Default Status Report”) in accordance with National Policy 12‑203 Management Cease Trade Orders (“NP 12-203”). On November 18, 2024, UI announced that it would delay the filing of its annual audited financial statements for the year ended July 31, 2024, its related management's discussion and analysis (“MD&A”), and the Chief Executive Officer and Chief Financial Officer certifications (collectively, the "Required Filings") past the prescribed deadline of Nove...

    Calgary, AB – January 22, 2025 – TheNewswire - Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, is pleased to advise it has closed the sale of its Belize Property. As previously announced (see prior News Releases dated November 26, December 11, and December 27, 2024 and January 13, 2025) the Company agreed to sell 100% of the shares of its wholly-owned subsidiary Universal Ibogaine Belize Ltd. (“UIBL”) for proceeds of USD 300,000 (the “Sale”).  UIBL owns no assets other than 20-acres of undeveloped land located on an island in offshore Belize (the “Belize Property”). The Sale proceeds of approximately Cdn $416,000 (net of Belize transaction costs) have been received and were held in Trust by the Company pending final regulatory approval of the TSX Venture Exchange (the “TSXV”), which has now been issued. As previously advised, the Sale was to a party that is related...

    Calgary, AB – January 13, 2025 – TheNewswire - Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, provides the following bi-weekly default status report update: Management Cease Trade Order (“MCTO”) Further to the Company's prior news releases (dated November 18, November 26, December 11 and December 27, 2024), the Company is providing this bi-weekly default status report (the “Default Status Report”) in accordance with National Policy 12‑203 Management Cease Trade Orders (“NP 12-203”). On November 18, 2024, UI announced that it would delay the filing of its annual audited financial statements for the year ended July 31, 2024, its related management's discussion and analysis (“MD&A”), and the Chief Executive Officer and Chief Financial Officer certifications (collectively, the "Required Filings") past the prescribed deadline of November 28, 2024. The ...

  Calgary, AB – TheNewswire - December 27, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, provides the following bi-weekly default status report update: Management Cease Trade Order (“MCTO”) Further to the Company's prior news releases (November 18, 26 and December 11, 2024), the Company is providing this bi-weekly default status report (the “Default Status Report”) in accordance with National Policy 12‑203 Management Cease Trade Orders (“NP 12-203”). On November 18, 2024, UI announced that it would delay the filing of its annual audited financial statements for the year ended July 31, 2024, its related management's discussion and analysis (“MD&A”), and the Chief Executive Officer and Chief Financial Officer certifications (collectively, the "Required Filings") past the prescribed deadline of November 28, 2024. The Company was granted a manageme...

  Calgary, AB – TheNewswire - December 11, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, provides the following bi-weekly default status report update: Management Cease Trade Order (“MCTO”) Further to the Company's prior news releases (November 18 and November 26, 2024), the Company is providing this bi-weekly default status report (the “Default Status Report”) in accordance with National Policy 12‑203 Management Cease Trade Orders (“NP 12-203”). On November 18, 2024, UI announced that it would delay the filing of its annual audited financial statements for the year ended July 31, 2024, its related management's discussion and analysis (“MD&A”), and the Chief Executive Officer and Chief Financial Officer certifications (collectively, the "Required Filings") past the prescribed deadline of November 28, 2024. The Company was granted a management ce...

  Calgary, AB – TheNewswire - November 26, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, is pleased to advise that it has received an offer to purchase (the “Offer”) its undeveloped 20-acre island property in Belize (the “Property”) for USD 300,000.   The Offer is to purchase the shares of Universal Ibogaine Belize Ltd. (“UIBL”), which holds title to the Property, has no operations, and is an inactive, wholly-owned subsidiary of the Company.  The Offer was made by an individual who is a Belize resident, who serves as a Director of UIBL, and has not been involved in any decision making or other capacity with UI.  The Offer has an expected closing date of December 6, 2024, is subject to receipt of any necessary regulatory approvals (including that of the TSX Venture Exchange) and includes a non-refundable deposit of USD 30,000 due by November 27 (the ?...

    Calgary, AB – November 18, 2024 – TheNewswire – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, advises that it has made an application to the Alberta Securities Commission (as Principal Regulator) and the British Columbia Securities Commission, to approve a temporary management case trade order (“MCTO”) under National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults (“NP 12-203”), which, if granted, will prohibit trading securities of the Company by the Chief Executive Officer and Chief Financial Officer of the Company until such time as the Required Filings (defined below) and all continuous disclosure requirements have been filed by the Company, and the MCTO has been lifted.  During the period in which the MCTO is in effect, the general public will continue to be able to trade in the Company's listed common shares.  The MCTO application has been...

  Calgary, AB – June 17, 2024 – TheNewswire – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises that it has reached an agreement to issue a total of 4,040,067 common shares at a price of $0.015 per share pursuant to a settlement of accounts payable of $60,601 (the “Settlement”). The securities will be issued subject to the approval of the TSX Venture Exchange (the “TSXV”) and will be subject to a four‐month hold period as required by the rules of the TSXV and Canadian Securities Laws. UI will have a total of 308,610,516 common shares issued and outstanding after closing of the Settlement. About Universal Ibogaine Inc.  UI is a life sciences company, with a mission to transform addiction treatment using medicalized ibogaine through a planned Canadian clinical trial focused on opioid use disorder, and ultimately to utilize that treatment protocol globally t...

  Calgary, AB – TheNewswire - June 7, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises that it has closed its previously announced (see News Release of April 12) non-brokered private placement offering of common shares (the “Offering”) and has issued a total of 13,500,000 common shares at a price of $0.02 per share for gross proceeds of $270,000.  No finders fees were payable on the Offering. The proceeds from the Offering are intended to be used in advancing the Company's planned ibogaine-based clinical trial application process with Health Canada, and for general working capital purposes. All securities issued in connection with the Offering will be subject to a four‐month hold period as required by the rules of the TSX Venture Exchange and Canadian Securities Laws, as well as any required hold periods under US Securities Laws for US resident pur...

  Calgary, AB – TheNewswire - June 7, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises that it has closed its previously announced (see News Release of April 12) non-brokered private placement offering of common shares (the “Offering”) and has issued a total of 13,500,000 common shares at a price of $0.02 per share for gross proceeds of $270,000.  No finders fees were payable on the Offering. The proceeds from the Offering are intended to be used in advancing the Company's planned ibogaine-based clinical trial application process with Health Canada, and for general working capital purposes. All securities issued in connection with the Offering will be subject to a four‐month hold period as required by the rules of the TSX Venture Exchange and Canadian Securities Laws, as well as any required hold periods under US Securities Laws for US resident pur...